Abstract:OBJECTIVE:To identify potential prognosis related clinical and molecular factors in malignant pleural mesothelioma (MPM).METHODS:Seventy-nine patients with MPM treated in Beijing Cancer Hospital from June 1996 to May 2012 were enrolled in this study. Clinical and pathological data were collected, including age, gender, smoking status, treatment, response, and molecular biomarkers such as thymidylate synthetase (TS) expression, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) gene rearrangement. The primary endpoint was overall survival (OS). SPSS 16.0 statistical analysis software was used for univariate analysis. The expression of TS was detected by immunohistochemistry (IHC). Fluorescence in situ hybridization (FISH) was performed to detect EML4-ALK gene rearrangement. Efficacy of the chemotherapy regimen including pemetrexed was analyzed with these molecular biomarkers.RESULTS:The median survival time (MST) of all patients was 15.5 months (95% CI: 10.6 - 20.4). Univariate survival analysis revealed that treatment factors including receiving operation, systemic chemotherapy, pemetrexed-based chemotherapy and capability of receiving second (or above) line chemotherapy were significantly related with OS. The MST of patients receiving operation was 5.4 months (95% CI: 3.6 - 7.3), significantly shorter than the 17.7months (95% CI: 11.8 - 23.5) in those who didn't receive operation (P = 0.030). Patients receiving systemic chemotherapy had a longer MST of 18.0 months (95% CI: 12.3 - 23.8) as compared to the 7.9 months (95% CI: 1.1 - 14.7) in those who didn't (P = 0.001). The MST of pemetrexed-based chemotherapy was 21.9 months (95% CI: 14.1-29.7) compared with 8.8 months (95% CI: 4.2 - 13.4) of regimens without pemetrexed (P = 0.000). For patients capable of receiving second (or above) line chemotherapy the MST was longer (21.0 months, 95% CI: 12.7 - 29.3) than those who could not (12.1 month, 95% CI: 6.4 - 17.8 month), P = 0.022. For the 42 patients treated with pemetrexed-based chemotherapy, the objective response rate (ORR) was 33.3% (14/42), the disease control rate (DCR) was 78.6% (33/42), the median progression-free survival (PFS) was 4.8 months (95% CI: 3.6 - 6.0) and MST was 21.9 months (95% CI: 14.1 - 29.7). Twenty-nine patients provided adequate specimens for detection of TS expression and 6 cases (20.7%) were positive. EML4-ALK gene rearrangement was studied in 32 patients and 6 (18.8%) were positive. TS expression was found to be inversely related to PFS of pemetrexed-based chemotherapy (P = 0.041). The MST was 19.6 months (95% CI: 6.0 - 7.9) in EML4-ALK-positive patients and 9.57 months (95% CI: 2.7 - 4.3) in negative ones (P = 0.159).CONCLUSIONS:Systemic chemotherapy especially pemetrexed-based regimen was proved to be a superior option for MPM with a significantly prolonged OS. Correlation between TS expression or EML4-ALK rearrangement and outcome of pemetrexed-based chemotherapy for MPM may contribute to future individualized treatment, which needs further validation from large-scale prospective studies.

Perspectives on the Treatment of Malignant Pleural Mesothelioma

[Advances in Immunotherapy for Malignant Pleural Mesothelioma].

Development of diagnosis and treatment on malignant pleural mesothelioma

Biomarker-guided Targeted and Immunotherapies in Malignant Pleural Mesothelioma

Current status of and progress in the treatment of malignant pleural effusion of lung cancer

[Advances in Targeted Therapy for Malignant Pleural Mesothelioma]

Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment

Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma

Advances in immunotherapy for pleural malignant mesothelioma

MA06.05 Targeting Anti-Apoptotic Mechanisms in Malignant Pleural Mesothelioma

Advances in diagnosis and management of malignant pleural mesothelioma

Research Progress in Malignant Pleural Effusion Therapy

[Prognosis Related Clinical and Molecular Factors in Malignant Pleural Mesothelioma].

Malignant pleural effusion: current understanding and therapeutic approach

Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma

New Horizons in Non-Small-cell Lung Cancer Patients with Ipsilateral Pleural Dissemination (m1a): Review of the Literature

Malignant pleural effusion: Updates in diagnosis, management and current challenges

Therapeutic Strategies to Improve the Treatment of Pleural Mesothelioma

Diffuse malignant peritoneal mesothelioma: A review

Molecular Changes in Mesothelioma With an Impact on Prognosis and Treatment

Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight